Respiratory syncytial virus vaccine: Is it coming?
Respiratory syncytial virus (RSV) is recognized as an important cause of childhood morbidity and mortality. Vaccine development has been challenging in young infants and has required the advent of molecular technologies to optimize the safety profile, while maintaining immunogenicity of live-attenuated vaccines. Protein-based vaccines have been evaluated in clinical trials and are promising candidates for RSV-primed populations or for maternal vaccination to provide early life protection. This review provides a summary of the need for an RSV vaccine, as well as the challenges and progress in the vaccine's development.
Sales
Valérie
V
Clinical Development, Aventis Pasteur Ltd, Toronto, Ontario;
Wang
Elaine El
EE